1h Free Analyst Time
The 3D Printed Drugs Market size was estimated at USD 292.72 million in 2023, USD 331.22 million in 2024, and is expected to grow at a CAGR of 14.26% to reach USD 744.29 million by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
3D printed drugs refer to the emerging use of 3D printing technology to create pharmaceutical products with improved drug delivery mechanisms. 3D printing of drugs enables personalization, precision, and cost-efficiency in drug manufacturing. The proliferation of 3D printed drugs is transforming the pharmaceutical industry, enabling the design of medications in any desired shape, size, dose, and delivery rate, delivering personalized healthcare for patients. Increased drug discovery and development activities and an inclination towards a personalized medicines approach are raising the need for advanced drug manufacturing techniques such as 3D printing of drugs. However, the high upfront cost of 3D printing technology may adversely impact the production of 3D printed drugs. Moreover, technological advancements in 3D printing technology are expected to enhance drug production efficiency, which is anticipated to expand its use for the development of drugs.
Regional Insights
The Americas have a significant landscape in the 3D-printed drugs market owing to progressive medical research and development, the robust pharmaceutical industry, and the presence of key 3D-printed drug manufacturers. Rising technological advancements and enhanced healthcare infrastructure further advance the market landscape in the region. Europe has observed a significant market for 3D printed drugs, driven by a rising geriatric population, initiatives towards personalized medicine, supportive governmental regulations, and funding activities from government and key manufacturers. In the Middle East & Africa, increasing investments in technological adoption and healthcare infrastructure enhancement contribute to market growth. The Asia-Pacific region is witnessing an emerging stage in the 3D printed drugs market and shows significant growth potential driven by factors such as rapid urbanization, innovations in healthcare technologies, increasing healthcare expenditures, and a rising elderly population requiring customized medication.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the 3D Printed Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the 3D Printed Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the 3D Printed Drugs Market, highlighting leading vendors and their innovative profiles. These include 3D Systems, Inc., 3DR HOLDINGS, Anatomics Pty Ltd, Aprecia Pharmaceuticals, LLC, AstraZeneca plc, BioDuro, LLC, Biomedical Modeling Inc., Cycle Pharmaceuticals, Cyfuse Biomedical K.K., EnvisionTEC GmbH, FabRx Ltd., General Electric Company, GlaxoSmithKline Plc, Materialise NV, Merck KGaA, Organovo Holdings Inc., Proto Labs Inc., Renishaw PLC, Rokit Healthcare Inc., Siemens AG, Stratasys Ltd., Triastek, Inc., TVASTA, Yissum, and Zortrax S.A.Market Segmentation & Coverage
This research report categorizes the 3D Printed Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:- Technology
- Direct-Write
- Fused Deposition Modelling
- Inkjet Printing
- Powder Bed Printing
- Stereolithography
- Zip Dose
- Dose Form
- Capsule
- Nanoparticles
- Tablet
- Application
- Dental
- Neurology
- Orthopedic
- End-User
- Clinics & Hospitals
- Research Laboratories
- Speciality Clinics
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the 3D Printed Drugs Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the 3D Printed Drugs Market?
- What are the technology trends and regulatory frameworks in the 3D Printed Drugs Market?
- What is the market share of the leading vendors in the 3D Printed Drugs Market?
- Which modes and strategic moves are suitable for entering the 3D Printed Drugs Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. 3D Printed Drugs Market, by Technology
7. 3D Printed Drugs Market, by Dose Form
8. 3D Printed Drugs Market, by Application
9. 3D Printed Drugs Market, by End-User
10. Americas 3D Printed Drugs Market
11. Asia-Pacific 3D Printed Drugs Market
12. Europe, Middle East & Africa 3D Printed Drugs Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix
List of Figures
List of Tables
Companies Mentioned
- 3D Systems, Inc.
- 3DR HOLDINGS
- Anatomics Pty Ltd
- Aprecia Pharmaceuticals, LLC
- AstraZeneca plc
- BioDuro, LLC
- Biomedical Modeling Inc.
- Cycle Pharmaceuticals
- Cyfuse Biomedical K.K.
- EnvisionTEC GmbH
- FabRx Ltd.
- General Electric Company
- GlaxoSmithKline Plc
- Materialise NV
- Merck KGaA
- Organovo Holdings Inc.
- Proto Labs Inc.
- Renishaw PLC
- Rokit Healthcare Inc.
- Siemens AG
- Stratasys Ltd.
- Triastek, Inc.
- TVASTA
- Yissum
- Zortrax S.A.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Published | March 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 331.22 Million |
| Forecasted Market Value ( USD | $ 744.29 Million |
| Compound Annual Growth Rate | 14.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
